Cavitation nucleation agents for nonthermal ultrasound therapy.
The use of a nucleation-promoting agent can greatly enhance therapeutically useful nonthermal bioeffects. A blank agent (saline), Optison ultrasound contrast agent, a stabilized perfluoropentane droplet suspension (SDS), and retained air space were compared as nucleation agents in whole blood. Fresh canine whole blood with added agent was exposed in 1.3-ml disposable pipette bulbs to lithotripter shock waves (2-Hz rate; +24.4, -5.2 MPa peak pressure amplitudes). Cavitation activity was assessed by measuring hemolysis. The droplet suspension performed nearly as well as retained air when added at a concentration sufficient to provide a roughly equal volume of gas after vaporization. Optison also yielded nucleation, but a concentration of 10%-20% was needed for large enhancement of hemolysis comparable to 5% SDS. Exposure at room temperature, which was less than the 29 degrees C boiling point of perfluoropentane, eliminated the enhancement of the hemolysis effect relative to the blank. Application of 100-kPa excess pressure during exposure reduced but did not eliminate the nucleation ability of Optison, SDS, or retained air. However, this small pressure (relative to the peak positive pressure of the shock waves) eliminated the hemolysis induced with the blank agent. The stabilized perfluoropentane droplet suspension appears to be a good nucleation agent for nonthermal ultrasound therapy applications.